Oculis ehf. is a rapidly expanding innovation company that is developing new eye drops for drug delivery to the anterior and posterior segments of the eye. The first product from Oculis is eye drops for diabetic macular edema which is currently in phase IIb trials. Oculis has offices in Reykjavík and Lausanne, Switzerland. Drug development takes place at a new laboratory in Reykjavik and the clinical trials program is performed in Europe and the United States. The Oculis team has long experience in ophthalmic drug development. 

Sjá nánar á www.oculis.com.
